Contrasting Contribution of 5-Hydroxytryptamine 1A Receptor Activation to Neurochemical Profile of Novel Antipsychotics: Frontocortical Dopamine and Hippocampal Serotonin Release in Rat Brain

@article{Assi2005ContrastingCO,
  title={Contrasting Contribution of 5-Hydroxytryptamine 1A Receptor Activation to Neurochemical Profile of Novel Antipsychotics: Frontocortical Dopamine and Hippocampal Serotonin Release in Rat Brain},
  author={Marie Bernadette Assi{\'e} and V{\'e}ronique Ravailhe and Val{\'e}rie Faucillon and Adrian Newman-Tancredi},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2005},
  volume={315},
  pages={265 - 272}
}
Several novel antipsychotics, such as aripiprazole, bifeprunox, SSR181507 [(3-exo)-8-benzoyl-N-(((2S)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl)methyl)-8-azabicyclo(3.2.1)octane-3-methanamine], and SLV313 [1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-piperazine], activate serotonin 5-hydroxytryptamine (5-HT)1A receptors. Such activity is associated with enhanced treatment of negative symptoms and cognitive deficits, which may be mediated by modulation of… Expand
Differential Effects of M 1 and 5-Hydroxytryptamine 1 A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex
Systemic administration of the M1 receptor agonists N-desmethylclozapine (NDMC) and 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) increase dopamine (DA) efflux inExpand
Differential Effects of M1 and 5-Hydroxytryptamine1A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex
TLDR
DA efflux in the mPFC induced by the atypical antipsychotic drugs clozapine, risperidone, and olanzapine is also mediated by M1 receptor stimulation and results suggest that the AC260584, NDMC-, and clozAPine-induced DA eff Lux in themPFC is mediated directly by mP FC M1 receptors. Expand
Correlating Efficacy in Rodent Cognition Models with in Vivo 5-Hydroxytryptamine1A Receptor Occupancy by a Novel Antagonist, (R)-N-(2-Methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane Carboxamide (WAY-101405)
TLDR
These studies demonstrate that WAY-101405 is a potent and selective, brain penetrant, orally bioavailable, silent 5-HT1A receptor “silent” antagonist that is effective in preclinical memory paradigms at doses where approximately 90% of the postsynaptic 5- HT1A receptors are occupied. Expand
SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug
TLDR
The results suggest that SLV313 is a full 5-HT1A receptor agonist and full D2/3 receptor antagonist possessing characteristics of an atypical antipsychotic, representing a potential novel treatment for schizophrenia. Expand
Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.
TLDR
It is suggested that the blockade of an exacerbated 5-HT release in the mPFC induced by NMDA antagonists can be a characteristic of atypical antipsychotic drugs, and it is proposed that D(2)/D(3/D(4) receptor antagonists would act predominantly on a subpopulation of GABAergic interneurons of themPFC, thus enhancing cortical inhibition, which would prevent an excessive glutamatergic transmission. Expand
F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
TLDR
Whereas SSR181507 exhibits (partial) agonism at dopamine D2 and 5-HT1A receptors, F15063 blocks dopamine D 2-like receptors whilst activating 5- HT1A antagonists and currently available antipsychotic drugs. Expand
Crystal structures of dual dopamine D2 and serotonin 5-HT1A active arylpiperidinyl-2(1H)-3,4-dihydroquinolinones
Abstract8-(1-((5-Cyclopentenylpyridin-3-yl)methyl)piperidin-4-yl)-3,4-dihydroquinolin-2(1H)-one (1) and 8-(1-(3- cyclopentenylbenzyl)piperidin-4-yl)-3,4-dihydroquinolin-2(1H)-one (2) are synthesizedExpand
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
TLDR
Ant antipsychotics display varying efficacies at serotonin 5-HT1A and dopamine D2S receptors which may play a major role in their differential functional profiles in blocking the diverse symptoms of schizophrenia. Expand
Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist.
TLDR
The in vitro - in vivo pharmacology profile of F17464 in preclinical models is discussed in support of a therapeutic use of the compound in schizophrenia and autism. Expand
The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor.
TLDR
d-threo-(R,R)-MPH appears to act as a selective 5-HT(1A) receptor agonist in vitro, and it is speculated that the activation of 5- HT(1a) receptor might play a partial role in d-THreo-MPH mediated dopamine (DA) release in the brain. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological Profile
TLDR
The combination of D2 receptor antagonism and 5-HT1A agonism, in the same dose range, confers on SSR181507 a unique neurochemical and electrophysiological profile and suggests the potential of this compound for the treatment of the main dimensions of schizophrenia. Expand
SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity
TLDR
The pharmacological profile of SSR181507 suggests that it should control the symptoms of schizophrenia, in the absence of extrapyramidal signs and cognitive deficits, with the additional benefit of antidepressant/anxiolytic activities. Expand
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
TLDR
It is demonstrated that aripiprazole, at low doses of 0.1 and 0.3 mg/kg, increases dopamine release in the medial prefrontal cortex and hippocampus, and suggests that the function of both the medial amygdala and hippocampus may contribute to the ability of aripIPrazole to improve negative symptom and cognition. Expand
Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.
TLDR
The biological significance of elevated 5-HT(1A) receptor density in schizophrenia remains unclear and needs to be viewed in light of preclinical evidence supporting a role for 5-hydroxytryptamine-1A receptors in mediating antipsychotic action and extrapyramidal adverse effects of drugs. Expand
5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
TLDR
It is confirmed that ziprasidone, like clozapine, acts as a 5-HT(1A) receptor agonist in vivo, which may contribute to its activity as an antipsychotic with efficacy against negative symptoms and a low extrapyramidal side effect liability. Expand
Estimation of apparent pA2 values for WAY 100635 at 5-HT1A receptors regulating 5-hydroxytryptamine release in anaesthetised rats.
TLDR
Evidence is shown that orderly microdialysis data can be obtained using cumulative dosing, which enables one to collect dose-response data rapidly, with fewer animals, and that buspirone, S 14506 and 8-OH-DPAT, administered in cumulative doses, decreased 5-HT release by activating similar5-HT1A receptors. Expand
The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
TLDR
The present data indicate that the 5-HT1A receptor agonist properties of nemonapride attenuate its ability to induce catalepsy at higher doses, and suggest further that tonic 5- HT1A receptors activation may modulate neuroleptic-induced catalEPsy. Expand
Serotonin receptors : their key role in drugs to treat schizophrenia
TLDR
5-HT has joined DA as a critical target for developing effective APDs and led to the search for novel drugs with complex pharmacology, ending the exclusive search for single-receptor targets. Expand
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
TLDR
S 16924 possesses a profile of interaction at multiple monoaminergic receptors comparable to that of clozapine and distinct to that that of haloperidol, and is a potent, partial agonist at 5-HT1A receptors. Expand
5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex
Background: Ziprasidone (Zeldox) is a novel antipsychotic with a unique combination of antagonist activities at monoaminergic receptors and transporters and potent agonist activity at serotoninExpand
...
1
2
3
4
5
...